https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/209 2025-12-26T15:54:19Z 2025-12-26T15:54:19Z Mo, Hyejin Kwon, Sukyung Kim, Daehwan Kim, Ye Jee Kim, Hyangkyoung Yang, Seung Boo Kwon, Young Joo Korean Soc Dialysis Access https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/63510 2024-12-14T02:01:15Z 2024-09-01T00:00:00Z

Title: Patency of arteriovenous fistulas and grafts for dialysis access: An analysis using the Korean National Health Insurance Service database from 2008 to 2019 Authors: Mo, Hyejin; Kwon, Sukyung; Kim, Daehwan; Kim, Ye Jee; Kim, Hyangkyoung; Yang, Seung Boo; Kwon, Young Joo; Korean Soc Dialysis Access Abstract: Background Arteriovenous (AV) access practice and its outcomes vary internationally. To provide a better understanding of the patterns and outcomes of AV access creation, we investigated the patency and risk factors of arteriovenous fistulas (AVFs) and grafts (AVGs) as initial AV access in the Korean adult population using data from the last 10 years. Methods The National Health Insurance Service database was queried retrospectively to identify patients undergoing hemodialysis with AVFs and AVGs as well as their clinical characteristics and outcomes from 2008 to 2019. AV access patency and its associated risk factors were evaluated. Results During the study period, 64,179 AVFs and 21,857 AVGs were placed. The mean patient age was 62.6 ± 13.6 years (21.5% were ⩾75 years old), and 39.3% patients were women. More than half of the patients underwent AV access creation at tertiary care hospitals. At 1 year, the primary, primary assisted, and secondary patency rates were 62.2%, 80.7%, and 94.2% for AVFs, and 46.0%, 68.4%, and 86.8% for AVGs, respectively. AVG, older age, female sex, diabetes, and creation at general hospitals (vs tertiary hospitals) were associated with decreased patency outcomes (all, p < 0.05). Conclusion This study using national data showed that three quarters of patients with AV access had AVF and AVF showed superior performance to AVG and identified several patient and center factors related to AV access patency in Korea.

2024-09-01T00:00:00Z Cha, Jin Joo Park, Boo Yeon Yoon, Sung Gi Park, Hye Jin Yoo, Ji Ae Ghee, Jung Yeon Cha, Dae Ryong Seong, Jae Young Kang, Young Sun https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/64143 2024-09-24T01:30:19Z 2023-12-01T00:00:00Z

Title: Spexin-based galanin receptor 2 agonist improves renal injury in mice with type 2 diabetes Authors: Cha, Jin Joo; Park, Boo Yeon; Yoon, Sung Gi; Park, Hye Jin; Yoo, Ji Ae; Ghee, Jung Yeon; Cha, Dae Ryong; Seong, Jae Young; Kang, Young Sun Abstract: The spexin-based GALR2 agonist (NS200) is a novel drug, which has shown antidepressant and anxiolytic action in a recent experimental study. In this study, we investigated the effects of NS200 on renal injury in an animal model of type 2 diabetes. Eight-week-old diabetic db/db mice were administered NS200 for 12 weeks. NS200 was intraperitoneally administered at a dose of 1.0 mg/kg/day. Metabolic parameters and structural and molecular changes in the kidneys were compared among the three groups: non-diabetic db/m control, db/db mice, and NS200-treated db/db mice. In db/db mice, NS200 administration did not impact the body weight, food and water intake, urinary volume, fasting blood glucose level, or HbA1c levels. Insulin and glucose tolerance were also unaffected by NS200 treatment. However, NS200 improved urinary albumin excretion and glomerulosclerosis in diabetic kidneys. Activation of TGF beta 1 and insulin signaling pathways, such as PI3 K /AKT/ERK, were inhibited by NS200. In conclusion, a spexin-based GALR2 agonist attenuated diabetic nephropathy by alleviating renal fibrosis in mice with type 2 diabetes. Spexin-based GALR2 agonists have considerable potential as novel treatment agents in diabetic nephropathy.

2023-12-01T00:00:00Z Park, Sungha Shin, Jinho Ihm, Sang Hyun Kim, Kwang-il Kim, Hack-Lyoung Kim, Hyeon Chang Lee, Eun Mi Lee, Jang Hoon Ahn, Shin Young Cho, Eun Joo Kim, Ju Han Kang, Hee-Taik Lee, Hae-Young Lee, Sunki Kim, Woohyeun Park, Jong-Moo https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/64377 2025-09-25T06:30:26Z 2023-11-01T00:00:00Z

Title: Resistant hypertension: consensus document from the Korean society of hypertension Authors: Park, Sungha; Shin, Jinho; Ihm, Sang Hyun; Kim, Kwang-il; Kim, Hack-Lyoung; Kim, Hyeon Chang; Lee, Eun Mi; Lee, Jang Hoon; Ahn, Shin Young; Cho, Eun Joo; Kim, Ju Han; Kang, Hee-Taik; Lee, Hae-Young; Lee, Sunki; Kim, Woohyeun; Park, Jong-Moo Abstract: Although reports vary, the prevalence of true resistant hypertension and apparent treatment-resistant hypertension (aTRH) has been reported to be 10.3% and 14.7%, respectively. As there is a rapid increase in the prevalence of obesity, chronic kidney disease, and diabetes mellitus, factors that are associated with resistant hypertension, the prevalence of resistant hypertension is expected to rise as well. Frequently, patients with aTRH have pseudoresistant hypertension [aTRH due to white-coat uncontrolled hypertension (WUCH), drug underdosing, poor adherence, and inaccurate office blood pressure (BP) measurements]. As the prevalence of WUCH is high among patients with aTRH, the use of out-of-office BP measurements, both ambulatory blood pressure monitoring (ABPM) and home blood pressure monitoring (HBPM), is essential to exclude WUCH. Non-adherence is especially problematic, and methods to assess adherence remain limited and often not clinically feasible. Therefore, the use of HBPM and higher utilization of single-pill fixed-dose combination treatments should be emphasized to improve drug adherence. In addition, primary aldosteronism and symptomatic obstructive sleep apnea are quite common in patients with hypertension and more so in patients with resistant hypertension. Screening for these diseases is essential, as the treatment of these secondary causes may help control BP in patients who are otherwise difficult to treat. Finally, a proper drug regimen combined with lifestyle modifications is essential to control BP in these patients.

2023-11-01T00:00:00Z Song, Je Hun Park, Eun Hee Bae, Jinsuk Kwon, Soon Hyo Cho, Jang-Hee Yu, Byung Chul Han, Miyeun Song, Sang Heon Ko, Gang-Jee Yang, Jae Won Chung, Sungjin Hong, Yu Ah Hyun, Young Youl Bae, Eunjin Sun, In O. Kim, Hyunsuk Hwang, Won Min Shin, Sung Joon Park, Woo Yeong Kim, Hyoungnae Yoo, Kyung Don https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/64341 2024-12-14T02:30:14Z 2023-10-01T00:00:00Z

Title: Effect of low-density lipoprotein level and mortality in older incident statin-naïve hemodialysis patients Authors: Song, Je Hun; Park, Eun Hee; Bae, Jinsuk; Kwon, Soon Hyo; Cho, Jang-Hee; Yu, Byung Chul; Han, Miyeun; Song, Sang Heon; Ko, Gang-Jee; Yang, Jae Won; Chung, Sungjin; Hong, Yu Ah; Hyun, Young Youl; Bae, Eunjin; Sun, In O.; Kim, Hyunsuk; Hwang, Won Min; Shin, Sung Joon; Park, Woo Yeong; Kim, Hyoungnae; Yoo, Kyung Don Abstract: Background This study aimed to analyze low-density lipoprotein cholesterol (LDL-C) levels and their relationship with mortality in order to identify the appropriate lipid profile for older Korean hemodialysis patients.Methods We enrolled a total of 2,732 incident hemodialysis patients aged > 70 years from a retrospective cohort of the Korean Society of Geriatric Nephrology from 2010 Jan to 2017 Dec, which included 17 academic hospitals in South Korea. Of these patients, 1,709 were statin-naive, and 1,014 were analyzed after excluding those with missing LDL-C level data. We used multivariate Cox regression analysis to select risk factors from 20 clinical variables among the LDL-C groups.Results The mean age of the entire patient population was 78 years, with no significant differences in age between quartiles Q1 to Q4. However, the proportion of males decreased as the quartiles progressed towards Q4 (p < 0.001). The multivariate Cox regression analysis, which included all participants, showed that low LDL-C levels were associated with all-cause mortality. In the final model, compared to Q1, the hazard ratios (95% confidence interval) were 0.77 (0.620-0.972; p = 0.027), 0.85 (0.676-1.069; p = 0.166), and 0.65 (0.519-0.824; p < 0.001) for Q2, Q3, and Q4, respectively, after adjusting for covariates, such as conventional and age-specific risk factors. The final model demonstrated that all-cause mortality increased as LDL-C levels decreased, as confirmed by a restrictive cubic spline plot.Conclusions In older hemodialysis patients who had not previously received dyslipidemia treatment, elevated LDL-C levels were not associated with increased all-cause mortality. Intriguingly, lower LDL-C levels appear to be associated with an unfavorable effect on all-cause mortality among high-risk hemodialysis patients.

2023-10-01T00:00:00Z